Assistive Technology for Persons with Alzheimer's Disease and Related Dementias and Their Caregivers (R41/R42, R43/R44 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Technology Transfer (STTR) research and development of assistive technology for individuals with Alzheimer's disease (AD) and AD-related dementias (ADRD) and their caregivers/care partners, to enhance their health and well-being, reduce illness and disability, and improve quality of life. Particularly of interest are technologies for providing psychosocial support (enhancing mood, mitigating the effects of loneliness, and enhancing social connection and communication), reducing stress (e.g., through the provision of biofeedback or other forms of behavioral therapy) and assisting with care management and activities of daily living. To achieve these ends, this FOA encourages a multidisciplinary approach to foster collaborations between geriatricians (particularly those with knowledge of cognitive impairment and dementia), psychologists, neurologists, computer scientists, and mechanical, electrical and software engineering professionals. Applications should demonstrate the potential for broad population impact, including that the proposed assistive technology is:

1. Innovative

2. Efficacious and effective

3. Scalable

4. Low-cost 

Companion FOA: PAR-18-588, R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): April 10, 2018, January 8, 2019, and January 8, 2020

PAR-18-587 Expiration Date January 9, 2020

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Amount Description

Budgets up to $500,000 total costs per year for Phase I and up to $1,000,000 total costs per year for Phase II may be requested.

Durations up to 1-2 years for Phase I and up to 2 years for Phase II may be requested.

    Funding Type





    Engineering and Physical Sciences
    Medical - Translational

    External Deadline

    January 8, 2020